Remimazolam in General Anesthesia: A Comprehensive Review of Its Applications and Clinical Efficacy
Top Cited Papers
Open Access
- 1 August 2024
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 18, 3487-3498
Abstract
Remimazolam is a novel ultra-short-acting benzodiazepine with a unique pharmacokinetic profile that makes it an attractive option for use in general anesthesia. This review paper provides an in-depth analysis of remimazolam’s applications in the field of general anesthesia, focusing on its pharmacological properties, clinical efficacy, safety profile, and potential advantages compared to other anesthetic agents. Remimazolam acts on GABAa receptors, offering rapid onset and recovery times due to its unique metabolic pathway involving tissue esterases. Clinical trials have demonstrated its efficacy in procedural sedation and general anesthesia, showing a favorable safety profile with minimal cardiovascular and respiratory depression. Compared to traditional anesthetics such as propofol, remimazolam presents distinct advantages, including predictable pharmacokinetics, reduced risk of prolonged sedation, and a reliable safety margin. These attributes position remimazolam as a promising agent in various clinical settings. The purpose of this review is to synthesize current evidence on remimazolam and discuss its potential to improve clinical outcomes in anesthesia practice.Keywords
This publication has 64 references indexed in Scilit:
- Remimazolam for anesthesia and sedation in pediatric patients: a scoping reviewJournal of Anesthesia, 2024
- Randomized controlled trial for anesthesia during gastroscopy: interactions between remimazolam and propofol in combination with sufentanilInternational Journal of Clinical Pharmacy, 2023
- Change in cerebral circulation during the induction of anesthesia with remimazolamJournal of Anesthesia, 2022
- Monitored anesthesia care with remimazolam for gynecological day surgeries: Case reportsClinical Case Reports, 2022
- Pharmacodynamic analysis of intravenous bolus remimazolam for loss of consciousness in patients undergoing general anaesthesia: a randomised, prospective, double-blind studyBritish Journal of Anaesthesia, 2022
- Remimazolam decreased the incidence of early postoperative nausea and vomiting compared to desflurane after laparoscopic gynecological surgeryJournal of Anesthesia, 2022
- Neurological sedative indicators during general anesthesia with remimazolamJournal of Anesthesia, 2022
- Remimazolam: A Review in Procedural SedationDrugs, 2021
- Pediatric sedation using dexmedetomidine and remimazolam for magnetic resonance imagingJournal of Anesthesia, 2021
- Remimazolam: Pharmacologic Considerations and Clinical Role in AnesthesiologyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016